The Impact of International Agreements on Health - Warren, Benjamin C.
59,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
30 °P sammeln
  • Broschiertes Buch

If we reform the granting of patent terms from a fixed twenty year life period to a flexible and adjustable term determined through an assessment of health and economic conditions that exist during any given time period, we will improve both global equity in access to medicines and reduce economic inefficiencies in our current model for pharmaceutical R&D, while maintaining adequate incentives to conduct pharmaceutical R&D. The reform is somewhat similar to the use of interest rates as an economic growth and stabilization tool in monetary policy. It would require government patent offices to…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
If we reform the granting of patent terms from a fixed twenty year life period to a flexible and adjustable term determined through an assessment of health and economic conditions that exist during any given time period, we will improve both global equity in access to medicines and reduce economic inefficiencies in our current model for pharmaceutical R&D, while maintaining adequate incentives to conduct pharmaceutical R&D. The reform is somewhat similar to the use of interest rates as an economic growth and stabilization tool in monetary policy. It would require government patent offices to analyze global conditions in pharmaceutical access and R&D, and accordingly adjust the number of years of patent protection awarded. This novel contribution to the academic literature informs decision makers on how to design appropriate innovation policy for the benefit of public health.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. Warren is an adjunct professor at the School of Population and Public Health, Faculty of Medicine, University of British Columbia. He currently does research and lectures on innovation policy and public health through analysis of equities in the global biotechnology and pharmaceutical industry.